April 1, 2019
Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor
RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections MENLO PARK, Calif.–(BUSINESS WIRE)–Recida…